Contineum Therapeutics Files 10-Q for Q1 2024

TL;DR

<b>Contineum Therapeutics reported a net loss of $16.9 million for Q1 2024, with no revenue and $15.9 million in cash.</b>

AI Summary

Contineum Therapeutics, Inc. (CTNM) filed a Quarterly Report (10-Q) with the SEC on May 16, 2024. Contineum Therapeutics reported total assets of $39,630,511 as of March 31, 2024. The company had total debt of $2,349,554 as of March 31, 2024. Contineum Therapeutics had $15,906,236 in cash and cash equivalents as of March 31, 2024. Revenue for the three months ended March 31, 2024, was $0. Net loss for the three months ended March 31, 2024, was $16,940,594.

Why It Matters

For investors and stakeholders tracking Contineum Therapeutics, Inc., this filing contains several important signals. The filing details Contineum Therapeutics' financial position as of the end of the first quarter of 2024, providing insight into its cash reserves and debt levels. Key events such as a reverse stock split and an IPO occurring after the reporting period are disclosed, indicating significant corporate activity post-Q1.

Risk Assessment

Risk Level: medium — Contineum Therapeutics, Inc. shows moderate risk based on this filing. The company is in the early stages of development with no revenue, indicating a high reliance on future funding and successful product development to achieve profitability.

Analyst Insight

Investors should monitor Contineum Therapeutics' cash burn rate and progress in its clinical pipeline, given its current lack of revenue.

Revenue Breakdown

Key Numbers

• 39,630,511 — Total Assets (As of March 31, 2024)
• 2,349,554 — Total Debt (As of March 31, 2024)
• 15,906,236 — Cash and Cash Equivalents (As of March 31, 2024)
• 16,940,594 — Net Loss (For the three months ended March 31, 2024)
• 0 — Revenue (For the three months ended March 31, 2024)
• 2024-03-31 — Reporting Period End Date (Quarterly report)
• 2024-05-16 — Filing Date (10-Q filing)

Key Players & Entities

• Contineum Therapeutics, Inc. (company) — Filer
• Pipeline Therapeutics, Inc. (company) — Former company name
• 2024-03-31 (date) — Period of report
• 2024-05-16 (date) — Filing date
• $39,630,511 (dollar_amount) — Total assets as of March 31, 2024
• $2,349,554 (dollar_amount) — Total debt as of March 31, 2024
• $15,906,236 (dollar_amount) — Cash and cash equivalents as of March 31, 2024
• $16,940,594 (dollar_amount) — Net loss for the three months ended March 31, 2024

FAQ

Risk Factors

• Net Loss [high — financial]: The company incurred a net loss of $16,940,594 for the three months ended March 31, 2024, indicating ongoing operational costs without corresponding revenue.
• Cash Burn [medium — financial]: With no revenue reported for the quarter, the company's substantial cash reserves are being depleted to fund operations, posing a risk if future funding or revenue generation is delayed.
• IPO Compliance [medium — regulatory]: As a recently public company, Contineum Therapeutics must adhere to ongoing SEC reporting and compliance requirements, which can be resource-intensive.

Key Financial Figures

• $0.001 — hich registered Class A Common Stock, $0.001 par value per share CTNM The Nasdaq
• $83.6 million — 2024, we had an accumulated deficit of $83.6 million. We have a limited operating history

Filing Documents

• cont20240331_10q.htm (10-Q) — 1437KB
• ex_651405.htm (EX-31.1) — 16KB
• ex_651406.htm (EX-31.2) — 12KB
• ex_651407.htm (EX-32.1) — 9KB
• ex_651408.htm (EX-32.2) — 6KB
• g01.jpg (GRAPHIC) — 84KB
• 0001437749-24-017320.txt (&nbsp;) — 5656KB
• ctnm-20240331.xsd (EX-101.SCH) — 37KB
• ctnm-20240331_cal.xml (EX-101.CAL) — 29KB
• ctnm-20240331_def.xml (EX-101.DEF) — 294KB
• ctnm-20240331_lab.xml (EX-101.LAB) — 254KB
• ctnm-20240331_pre.xml (EX-101.PRE) — 314KB
• cont20240331_10q_htm.xml (XML) — 795KB

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 21 Item 1A.

Risk Factors

Risk Factors 21 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 56 Item 3. Defaults Upon Senior Securities 56 Item 4. Mine Safety Disclosures 56 Item 5. Other Information 56 Item 6. Exhibits 57

Signatures

Signatures 59 Table of Contents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. CONTINEUM THERAPEUTICS, INC. CONDENSED BALANCE SHEETS (unaudited) (in thousands, except share and par value data) March 31, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 16,264 $ 15,526 Marketable securities 101,643 109,664 Prepaid expenses and other current assets 1,804 2,516 Total current assets 119,711 127,706 Property and equipment, net 756 678 Other long-term assets 2,623 1,283 Operating lease right-of-use assets 474 719 Total assets $ 123,564 $ 130,386 Liabilities, convertible preferred stock and stockholders' deficit Current liabilities: Accounts payable $ 570 $ 635 Accrued expenses 5,190 4,385 Current portion of operating lease liabilities 474 464 Total current liabilities 6,234 5,484 Other long-term liabilities 228 110 Operating lease liabilities, net of current portion 111 108 Total liabilities 6,573 5,702 Convertible preferred stock, $ 0.001 par value; authorized shares— 16,940,594 at March 31, 2024 and December 31, 2023; issued shares and outstanding shares— 15,906,236 at March 31, 2024 and December 31, 2023; $ 193,462 aggregate liquidation preference at March 31, 2024 192,620 192,620 Stockholders' deficit: Common stock, $ 0.001 par value; authorized shares— 39,630,511 at March 31, 2024 and December 31, 2023, respectively; issued shares— 2,384,426 and 2,349,554 at March 31, 2024 and December 31, 2023 respectively; outstanding shares— 2,384,426 and 2,349,554 at March 31, 2024 and December 31, 2023 respectively. 2 2 Additional paid-in-capital 7,988 7,098 Accumulated deficit ( 83,561 ) ( 75,144 ) Accumulated other comprehensive income (loss) ( 58 ) 108 Total stockholders' deficit ( 75,629 ) ( 67,936 ) Total liabilities, convertible preferred stock and stockholders' deficit $ 123,564 $ 130,386 The accompanying notes are an integral part of these unaudited condensed financial statements. 1 Table of Contents CONT

View Full Filing

View this 10-Q filing on SEC EDGAR